Phase 2Data readout

VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker)

Eosinophilic Esophagitis

PHATPhathom Pharmaceuticals

Expected catalystDecember 31, 2026Company guidance: Dec 31, 2026

Catalyst overview

Event details

Drug or asset: VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker)
Development stage: Phase 2
Event type: Data readout
Indication: Eosinophilic Esophagitis

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for VOQUEZNA® (Vonoprazan)(potassium competitive acid blocker) in Eosinophilic Esophagitis. The expected timing is based on the latest available company guidance and may change.

Development notes

07/30/26:- Ph2 pHalcon-EoE-201 enrollment completed; topline data expected Q4 2026.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source